Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04989699 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
A Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 6
- Study locations
NCT04989699 is a Phase 1 study of Neovascular Age-related Macular Degeneration that has completed, run by Ocular Therapeutix. The registered enrollment target is 21 participants, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT04989699, a Phase 1 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 6
- Study locations
Study Summary
Evaluate the safety, tolerability, and efficacy of OTX-TKI for intravitreal use in subjects with Neovascular Age-Related Macular Degeneration
Conditions Studied
Interventions
- DRUG OTX-TKI/Sham
- DRUG Aflibercept/Sham
Study Locations (6)
California
- Ocular Therapeutix - Bakersfield
- Ocular Therapeutix - Oxnard
Florida
- Ocular Therapeutix - Altamonte Springs
- Ocular Therapeutix - St. Petersburg
Nevada
- Ocular Therapeutix - Reno
Texas
- Ocular Therapeutix - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2023-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04989699
The ClinicalTrials.gov registry entry for NCT04989699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (95% lower). The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which OTX-TKI/Sham is the first listed.
NCT04989699 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Nevada.
Frequently Asked Questions
What is clinical trial NCT04989699 about?
NCT04989699 is a clinical study titled "Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration". Evaluate the safety, tolerability, and efficacy of OTX-TKI for intravitreal use in subjects with Neovascular Age-Related Macular Degeneration
What is the current status of trial NCT04989699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2021-07-28. Estimated completion is 2023-12-18.
What conditions does trial NCT04989699 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT04989699?
The interventions under investigation include: OTX-TKI/Sham (DRUG), Aflibercept/Sham (DRUG).
Who is sponsoring clinical trial NCT04989699?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04989699 being conducted?
This trial has 6 study locations across California, Florida, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
ACTIVE NOT RECRUITING · Phase 1
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
COMPLETED · Phase 1
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.